| Budget Amount *help |
¥51,610,000 (Direct Cost: ¥39,700,000、Indirect Cost: ¥11,910,000)
Fiscal Year 2014: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
Fiscal Year 2013: ¥10,010,000 (Direct Cost: ¥7,700,000、Indirect Cost: ¥2,310,000)
Fiscal Year 2012: ¥10,530,000 (Direct Cost: ¥8,100,000、Indirect Cost: ¥2,430,000)
Fiscal Year 2011: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
Fiscal Year 2010: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
|
|---|
| Outline of Final Research Achievements |
We previously reported that higher levels of plasma pentosidine, a well known biomarker for AGEs, and decreased serum pyridoxal levels were found in a subpopulation of schizophrenic patients. However, there is as yet no clinical characterization of this subset of schizophrenia. In this study, we found that these patients shared many clinical features with treatment resistant schizophrenia, as defined by Kane et al. These include a higher proportion of in-patients, low educational status, higher frequency and longer duration of hospitalization, and higher doses of anti-psychotic medication compared to patients without carbonyl stress. Interestingly, a number of psychopathological symptoms showed significant association with serum vitamin B6 levels. Our results support the idea that treatment regimes reducing carbonyl stress, such as supplementation of pyridoxamine could provide novel therapeutic benefits for this subgroup of patients.
|
